Navigation Links
Golden Meditech Celebrates Grand Opening of Taiwan Representative Office
Date:9/6/2011

HONG KONG, Sept. 6, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ("Golden Meditech", together with its subsidiaries collectively as the "Group", - 801.HK; 910801.TW), which embodies a leading medical devices enterprise, a major brand name in haematology hospital and the largest stem cell cord blood banking operator in China, is pleased to announce the launch of its Taiwan representative office today.

With a track record in China for establishing the largest stem cell cord blood banking corporation, developing a premium hospital service business, and now, building a cross-straits healthcare enterprise, Mr. Kam Yuen, Chairman and CEO of Golden Meditech, in known as a pioneer in China's healthcare industry. With his remarkable insights and ability to stay ahead of industry trends while having the attention and tenacity as an entrepreneur, Mr. Kam has set his sight on the substantial opportunities in Taiwan's medical and bio-tech industries. The Group has already set foot in Taiwan via issuing Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange in January 2011. Mr. Kam is of the view that the launch of Economic Cooperation Framework Agreement ("ECFA") and the policy allowing for easier access between the straits will foster the development of premium healthcare service sector. Whereas Taiwan has readily accessible medical expertise and resources, with the launch of the new Taiwan representative office, the Group will be able to better leverage its operative advantage, expand its industry reach and create greater opportunities with its Taiwan counterpart for greater growth.  

Golden Meditech is the first and one the largest blood-related medical device manufacturers in China with its key product, the Autologous Blood Recovery System ("ABRS") accounting for 80% share of the top-tier hospital market. China's ongoing medical reform has created an excellent opportunity for the Group as a pioneer in the areas of hospital services and hospital management. The Group's hospital management business is the first wholly-owned foreign entity to provide nation-wide hospital management services in China while its specialist haematology hospitals, operated under the "Daopei Hospital" brand, is a name to be reckoned in its specialty. Just recently, the Group has acquired a reputable operation, the Shanghai East International Medical Centre in Shanghai, to further strengthen its strategic position as a premium medical service provider

The Group's healthcare service portfolio also includes the first dedicated medical insurance information process and claims settlement business process outsourcing (BPO) service provider, GM Medicare Company Limited, launched in April 2011, and a stake in China Cord Blood Corporation ("CCBC"; NYSE listed stock code CO:US), the largest cord blood banking operator in China and a major shareholder of CORDLIFE LTD, a leading pan-Asian cord blood bank operator.

China's medical reform will be a key focus in the Twelve National People's Congress's Five-Year-Plan. The Group's healthcare services business will be a key beneficiary of the reform and a key growth driver to its growing business operations. Mr. Kam believes the progressive nature of the new medical reform and the ECFA has orchestrated the perfect opportunity for healthcare enterprises across the straits to form strategic partnerships and create a platform to connect and leverage on each other's strengths and capabilities. Golden Meditech maintains a positive outlook on Taiwan's healthcare industry, as the Group anticipates new opportunities for growth and collaboration with its ample resources in experience and competitive advantages. As it expands it foothold in Taiwan, the Group is also looking forward to identify suitable management talents and medical professions with its Taiwanese partners for even greater achievements In the future.

About Golden Meditech Holdings LimitedGolden Meditech Holdings Limited is China's leading integrated-healthcare devices and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx) and the Taiwan Stock Exchange (TSE). Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.For more information, please contact:Investor Relations DepartmentGolden Meditech Holdings LimitedAddress: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong KongTel:   +852-3605-8180Fax:   +852-3605-8181Email: ir@goldenmeditech.com
'/>"/>

SOURCE Golden Meditech Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Meditech FY2010-11 Annual Results
2. Golden Meditech Acquires Shanghai East International Medical Centre
3. Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5%
4. Golden Meditech Chairman Increases Stake in Company
5. Fenwal, Golden Meditech Complete Definitive Agreement to Form Joint Venture in China
6. Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business
7. Golden Meditech to Form Strategic Alliance with Long Bon International
8. Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
9. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
10. Golden Meditech Announces Annual Results for FY 2009/10
11. Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... Myeloid Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights 2016, provides comprehensive insights ... Myeloid Leukemia epidemiology, Acute Myeloid Leukemia market ...
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... Seminars for Business Journalists , led by the Wharton School’s most prominent ... issues.  This one-day program at the Wharton School’s San Francisco campus will ...
(Date:5/5/2016)... Cambridge, MA (PRWEB) , ... May 05, 2016 ... ... distinctions among workers’ compensation laws in all U.S. states and certain Canadian provinces ... (IAIABC) and the Workers Compensation Research Institute (WCRI). , The report, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Tim Dieter has ... families of greater Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center ... Donations to Veteran’s Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial Plastic ... Dr. Stong is double board certified and the only facial plastic surgeon in ... hair loss. Non-surgical therapies such as stem cells can be used to provide stabilization ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... on the eve of National Nurses Week (May 6-12). Currently, HireNurses is ... With their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically ...
Breaking Medicine News(10 mins):